Geron Appoints Vice President, Pharmacovigilance and Drug Safety
17 janv. 2019 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the hiring of the first of several key leadership positions as it rebuilds the in-house...
Geron Announces New Board Leadership Structure
31 déc. 2018 07h30 HE
|
Geron Corporation
CEO John A. Scarlett Appointed Chairman Karin Eastham Appointed Lead Independent Director MENLO PARK, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced...
Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
03 déc. 2018 16h22 HE
|
Geron Corporation
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) --...
Geron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting
03 déc. 2018 06h00 HE
|
Geron Corporation
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial...
Geron to Host Analyst and Investor Event on December 10, 2018
28 nov. 2018 17h30 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company’s analyst and investor event will take place in New York, N.Y., on Monday,...
Geron to Present at Upcoming Investor Conferences in November
07 nov. 2018 16h30 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present a...
Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
01 nov. 2018 16h05 HE
|
Geron Corporation
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology...
Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
01 nov. 2018 06h20 HE
|
Geron Corporation
Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Geron...
Geron Announces Discontinuation of Imetelstat Collaboration by Janssen
27 sept. 2018 06h00 HE
|
Geron Corporation
Geron regains global rights to imetelstat programHighlights reported for IMerge and IMbarkGeron plans to initiate the Phase 3 portion of IMergeConference call scheduled for 8:00 a.m. ET today MENLO...
Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018
26 sept. 2018 20h30 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to provide an update on the imetelstat collaboration with...